Experts debate wisdom of tapering bDMARDs in patients with low disease activity


This year’s Great Debate focused on the value of tapering biologic DMARDs in patients with rheumatoid arthritis who have achieved low disease activity. Paul Emery, MD, MA, FRCP, Arthritis Research UK Professor of Rheumatology, Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds ...


Already a member? Login to keep reading


OR
© 2017 the limbic